id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_buru5lq4zncjnlvci4nw4zjzpu	Shadia Jalal	Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study	2009	4	.pdf	application/pdf	3665	331	63	Introduction: Small cell lung cancer (SCLC) is initially a chemotherapy-sensitive disease. II study of pemetrexed in patients with relapsed SCLC. differentiated neuroendocrine cancers of the lung, Eastern Cooperative Oncology Group performance status of 0 to 2, and had received Both chemotherapy-sensitive (relapse �90 days from completion of first line therapy) and chemotherapy-resistant (progressive disease during or within 90 days from Despite an initial response to chemotherapy, patients with SCLC inevitably relapse and progress Our study evaluated single agent pemetrexed in relapsed SCLC and did not meet the predetermined criteria for Journal of Thoracic Oncology • Volume 4, Number 1, January 2009 Pemetrexed beyond Small Cell Lung Cancer III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study	./cache/work_buru5lq4zncjnlvci4nw4zjzpu.pdf	./txt/work_buru5lq4zncjnlvci4nw4zjzpu.txt